Standout Papers

Mortality from Coronary Heart Disease in Subjects with Type 2 Diabetes and in Nondiabetic Subj... 1998 2026 2007 2016 5.0k
  1. Mortality from Coronary Heart Disease in Subjects with Type 2 Diabetes and in Nondiabetic Subjects with and without Prior Myocardial Infarction (1998)
    Steven M. Haffner, Seppo Lehto et al. New England Journal of Medicine
  2. Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy (2006)
    Steven E. Kahn, Steven M. Haffner et al. New England Journal of Medicine
  3. Chronic Subclinical Inflammation as Part of the Insulin Resistance Syndrome (2000)
    Andreas Festa, Ralph B. D’Agostino et al. Circulation
  4. Metabolic Syndrome With and Without C-Reactive Protein as a Predictor of Coronary Heart Disease and Diabetes in the West of Scotland Coronary Prevention Study (2003)
    Naveed Sattar, Allan Gaw et al. Circulation
  5. NCEP-Defined Metabolic Syndrome, Diabetes, and Prevalence of Coronary Heart Disease Among NHANES III Participants Age 50 Years and Older (2003)
    Charles M. Alexander, Pamela B. Landsman et al. Diabetes
  6. Prospective Analysis of The Insulin-Resistance Syndrome (Syndrome X) (1992)
    Steven M. Haffner, Rodolfo Valdéz et al. Diabetes
  7. Elevated Levels of Acute-Phase Proteins and Plasminogen Activator Inhibitor-1 Predict the Development of Type 2 Diabetes (2002)
    Andreas Festa, Ralph B. D’Agostino et al. Diabetes
  8. Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes (2012)
    Hans‐Henrik Parving, Barry M. Brenner et al. New England Journal of Medicine
  9. Effect of Rosiglitazone Treatment on Nontraditional Markers of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus (2002)
    Steven M. Haffner, Andrew S. Greenberg et al. Circulation
  10. The Homeostasis Model in the San Antonio Heart Study (1997)
    Steven M. Haffner, Heikki Miettinen et al. Diabetes Care
  11. The Effect of Metformin and Intensive Lifestyle Intervention on the Metabolic Syndrome: The Diabetes Prevention Program Randomized Trial (2005)
    Trevor J. Orchard, Marinella Temprosa et al. Annals of Internal Medicine
  12. The Metabolic Syndrome as Predictor of Type 2 Diabetes (2003)
    Carlos Lorenzo, Ken Williams et al. Diabetes Care
  13. Management of Dyslipidemia in Adults With Diabetes (1998)
    Steven M. Haffner Diabetes Care
  14. Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes (2003)
    Donna H. Ryan, Mark A. Espeland et al. Controlled Clinical Trials
  15. Cardiovascular Risk Factors in Confirmed Prediabetic Individuals (1990)
    Steven M. Haffner JAMA
  16. International Day for the Evaluation of Abdominal Obesity (IDEA) (2007)
    Beverley Balkau, John Deanfield et al. Circulation
  17. Effect of Pioglitazone Compared With Glimepiride on Carotid Intima-Media Thickness in Type 2 Diabetes (2006)
    Theodore Mazzone, Peter Meyer et al. JAMA
  18. Does the Metabolic Syndrome Improve Identification of Individuals at Risk of Type 2 Diabetes and/or Cardiovascular Disease? (2004)
    Michael P. Stern, Ken Williams et al. Diabetes Care
  19. Homeostasis Model Assessment of Insulin Resistance in Relation to the Incidence of Cardiovascular Disease (2002)
    Anthony J. Hanley, Ken Williams et al. Diabetes Care

Immediate Impact

9 from Science/Nature 165 standout
Sub-graph 1 of 16

Citing Papers

Mechanisms and disease consequences of nonalcoholic fatty liver disease
2021 Standout
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
2020 Standout
15 intermediate papers

Works of Steven M. Haffner being referenced

Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes
2012 Standout
Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design
2009
and 8 more

Author Peers

Author Last Decade Papers Cites
Steven M. Haffner 32314 14145 14565 517 60.5k
Gerald M. Reaven 29768 13117 10960 663 58.0k
Naveed Sattar 22026 13539 14746 1.2k 70.7k
Jaakko Tuomilehto 22298 8795 12064 757 59.1k
Markku Laakso 22794 9547 12751 667 56.6k
Robert H. Eckel 21191 14005 14183 234 62.8k
Ronald M. Krauss 17976 7413 9433 378 47.3k
Julie E. Buring 12151 10461 15309 596 64.0k
Nader Rifai 16018 20990 20862 450 75.0k
Hertzel C. Gerstein 25805 5464 12016 496 49.6k
Ele Ferrannini 28308 7910 6815 523 50.0k

All Works

Loading papers...

Rankless by CCL
2026